$2.51
+0.18 (+7.73%)
Open$2.41
Previous Close$2.33
Day High$2.52
Day Low$2.39
52W High$43.98
52W Low$34.26
Volume—
Avg Volume422.0K
Market Cap241.63M
P/E Ratio21.06
EPS$1.81
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+1,485.3% upside
Current
$2.51
$2.51
Target
$39.79
$39.79
$29.42
$39.79 avg
$58.63
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 65.93M | 59.67M | 56.91M |
| Net Income | 10.90M | 11.06M | 10.11M |
| Profit Margin | 16.5% | 18.5% | 17.8% |
| EBITDA | 19.62M | 16.47M | 16.10M |
| Free Cash Flow | 6.94M | 6.70M | 7.67M |
| Rev Growth | +19.8% | +7.9% | +20.9% |
| Debt/Equity | 0.22 | 0.21 | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |